MILAN, ITALY--(Marketwire - March 12, 2008) - Milan, 12 March 2008 - Recordati announced the completion of the mutual recognition process for the approval throughout the European Union, in Norway and in Iceland, of its new antihypertensive specialty based on a fixed combination of lercanidipine and enalapril. Germany acted as Reference Member State and the 28 Concerned Member States decided to recognize the approval granted in 2006 by the German medicines agency (BfArM) of this new product in its two dosage forms containing lercanidipine 10mg/enalapril 10mg and lercanidipine 10mg/enalapril 20mg. The product is already on the market in Germany as from 2007.
